ABUS vs C
Arbutus Biopharma Corp (ABUS) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the ABUS and C stock pages for the full models.
Not investment advice.